Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer - PubMed (original) (raw)
Review
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer
R Ferraldeschi et al. Annu Rev Med. 2013.
Abstract
Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the response to treatment is not durable, and transition to a "castration-resistant" state is invariable. Recent advances in our understanding of the androgen receptor signaling pathway have led to the development of therapeutic strategies to overcome castration resistance. This article reviews current concepts and challenges behind targeting continued androgen receptor signaling in castration-resistant prostate cancer and provides an overview of recently completed and ongoing clinical trials of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).
Similar articles
- Overcoming castration resistance in prostate cancer.
Tsao CK, Small AC, Galsky MD, Oh WK. Tsao CK, et al. Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Curr Opin Urol. 2012. PMID: 22472508 Review. - New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N. Sharifi N. Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Expert Opin Investig Drugs. 2010. PMID: 20524793 Review. - Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
Pinto Á. Pinto Á. Cancer Biol Ther. 2014 Feb;15(2):149-55. doi: 10.4161/cbt.26724. Epub 2013 Nov 1. Cancer Biol Ther. 2014. PMID: 24100689 Free PMC article. Review. - Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR, Hussain MH. MacVicar GR, et al. Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Curr Opin Oncol. 2013. PMID: 23511665 Review. - Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R. Nandha R. J Postgrad Med. 2012 Jul-Sep;58(3):203-6. doi: 10.4103/0022-3859.101400. J Postgrad Med. 2012. PMID: 23023354 Review.
Cited by
- Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.
Heath EI, Chen W, Heilbrun L, Choi JE, Dobson K, Smith M, Maj T, Vaishampayan U, Kryczek I, Zou W, Chinnaiyan AM, Qiao Y. Heath EI, et al. Invest New Drugs. 2024 Sep 3. doi: 10.1007/s10637-024-01463-x. Online ahead of print. Invest New Drugs. 2024. PMID: 39227508 - Vernonia amygdalina Delile Induces Apoptotic Effects of PC3 Cells: Implication in the Prevention of Prostate Cancer.
Yedjou CG, Johnson W, Tchounwou SS, Dasari S, Njiki S, Tchounwou PB. Yedjou CG, et al. J Biomed Res Environ Sci. 2022 Oct;3(9):1118-1124. doi: 10.37871/jbres1564. Epub 2022 Sep 30. J Biomed Res Environ Sci. 2022. PMID: 36578651 Free PMC article. - Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP, Shen C, Zhou WF, Wang YX, Shan LH, Chai X, Shao Y, Hu XP, Zhu F, Zhu DY, Xiao L, Xu L, Xu XH, Li D, Hou TJ. Pang JP, et al. Acta Pharmacol Sin. 2022 Jan;43(1):229-239. doi: 10.1038/s41401-021-00632-5. Epub 2021 Mar 25. Acta Pharmacol Sin. 2022. PMID: 33767381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical